标签归档：mmp

CL-82198

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CL-82198  纯度: 99.78%

CL-82198 是一个选择性的 MMP-13 抑制剂。CL-82198 与 MMP-13 的整个 S1′ 口袋结合，这是其对 MMP-13 选择性和对其他 MMP 缺乏抑制活性的基础。CL-82198 可用于骨关节炎 (OA) 的研究。

CL-82198

CL-82198 Chemical Structure

CAS No. : 307002-71-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥605 In-stock
5 mg ￥550 In-stock
10 mg ￥880 In-stock
25 mg ￥1800 In-stock
50 mg ￥2900 In-stock
100 mg ￥5300 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

CL-82198 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Differentiation Inducing Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library

生物活性

CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs[1][2]. CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression[4].

体外研究
(In Vitro)

CL-82198 (10 μM; 24 hours) significantly reduces LS174 cell migration[1].
CL-82198 decreases CTGF and TGF-β1 protein levels in hepatic stellate cells[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

CL82198 (1-10 mg/kg; i.p.; every other day for 12 weeks) prevents and decelerates MLI-induced osteoarthritis progression[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 10-week-old C57BL/6J mice (performed MLI surgery)[4]
Dosage: 1, 5, 10 mg/kg body weight
Administration: Intraperitoneal injection; every other day for 12 weeks
Result: Prevented and decelerated MLI-induced osteoarthritis progression.

分子量

302.37

Formula

C17H22N2O3
CAS 号

307002-71-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (330.72 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.3072 mL 16.5360 mL 33.0721 mL
5 mM 0.6614 mL 3.3072 mL 6.6144 mL
10 mM 0.3307 mL 1.6536 mL 3.3072 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.27 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.27 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.27 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Rath T et al. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett. 2011 May;2(3):483-488.

    [2]. George J, et al. MMP-13 deletion decreases profibrogenic molecules and attenuates N-nitrosodimethylamine-induced liver injury and fibrosis in mice. J Cell Mol Med. 2017 Dec;21(12):3821-3835.

    [3]. Wohlauer M et al. Nebulized hypertonic saline attenuates acute lung injury following trauma and hemorrhagic shock via inhibition of matrix metalloproteinase-13. Crit Care Med. 2012 Sep;40(9):2647-53.

    [4]. Wang M,et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013 Jan 8;15(1):R5.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NSC 405020

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NSC 405020  纯度: 99.75%

NSC 405020 是MT1-MMP抑制剂，能特异地靶向MT1-MMP的PEX结构域，不会抑制MT1-MMP和MMP-2的催化活性。

NSC 405020

NSC 405020 Chemical Structure

CAS No. : 7497-07-6

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥785 In-stock
10 mg ￥714 In-stock
50 mg ￥2727 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

NSC 405020 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Differentiation Inducing Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library

生物活性

NSC 405020 is a novel small molecule inhibitor of MT1-MMP that specifically targets PEX domain rather than the catalytic domain of MT1-MMP with IC50 >100 μM and does not inhibit the catalytic activity of MT1-MMP or MMP-2. IC50 value: > 100 uM [1] Target: MT1-MMP PEX inhibitor NSC-405020 directly interacts with and binds to PEX in a vicinity of Met-328, Arg-330, Asp-376, Met-22 and Ser-470 of the druggable pocket in the full-length MT1-MMP structure, which affects the conformation and flexibility of blades I to IV of the β-propeller resulting in the decrease of the PEX-dependent homodimerization of cellular MT1-MMP. NSC-405020 dose not affect the ability of MT1-MMP to activate MMP-2 but its ability to degrade COL-I.

分子量

260.16

Formula

C12H15Cl2NO
CAS 号

7497-07-6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 260 mg/mL (999.38 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.8438 mL 19.2189 mL 38.4379 mL
5 mM 0.7688 mL 3.8438 mL 7.6876 mL
10 mM 0.3844 mL 1.9219 mL 3.8438 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (9.61 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (9.61 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Remacle AG, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 2012 May 1;72(9):2339-49.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

S 3304

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

S 3304  纯度: 99.11%

S 3304 是一个新型的基质金属蛋白酶 (MMP) 抑制剂, 且对 MMP-2 和 MMP-9 有特异的抑制活性。

S 3304

S 3304 Chemical Structure

CAS No. : 203640-27-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3373 In-stock
1 mg ￥1100 In-stock
5 mg ￥3300 In-stock
10 mg ￥5500 In-stock
25 mg ￥11000 In-stock
50 mg ￥16500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

S 3304 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Drug Repurposing Compound Library
  • Differentiation Inducing Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library

生物活性

S 3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9.

IC50 & Target

MMP-9

 

体外研究
(In Vitro)

S 3304 is a novel D-tryptophan derivative and a potent, orally active, noncytotoxic Matrix metalloproteinases inhibitor (MMPI). Biochemical studies show that S 3304 most potently inhibits the activities of MMP-2 and MMP-9 but does not inhibit MMP-1, MMP-3, or MMP-7 and may, therefore, lack the musculoskeletal side effects seen with nonspecific inhibitors[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

In vivo pharmacologic studies have shown that the oral administration of S 3304, at a dose range of 20 to 200 mg/kg, inhibits angiogenesis, artificially induced in mice by the dorsal air-sac method. Similar oral doses of S 3304 result in potent inhibition of metastatic lung colonization of Lewis murine lung carcinoma injected via tail vein and liver metastasis of C-1H human colon cancer implanted into the spleen[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

464.56

Formula

C24H20N2O4S2
CAS 号

203640-27-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 83.3 mg/mL (179.31 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1526 mL 10.7629 mL 21.5257 mL
5 mM 0.4305 mL 2.1526 mL 4.3051 mL
10 mM 0.2153 mL 1.0763 mL 2.1526 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.38 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (5.38 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (5.38 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Chiappori AA, et al. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Actinonin(Synonyms: (-)-Actinonin)

发表于由

Actinonin (Synonyms: (-)-Actinonin) 纯度: 99.30%

Actinonin ((-)-Actinonin) 是一种由放线菌产生的天然抗菌剂。Actinonin 抑制氨肽酶 M，氨肽酶 N 和亮氨酸氨肽酶。Actinonin 是一种有效的可逆肽去甲酰基酶 (PDF) 抑制剂，Ki 为 0.28 nM。Actinonin 还抑制 MMP-1，MMP-3，MMP-8，MMP-9 和 hmeprin α 的 Ki 值分别为 300 nM，1,700 nM，190 nM，330 nM 和 20 nM。Actinonin 是一种凋亡诱导剂，具有抗增殖和抗肿瘤活性。

Actinonin(Synonyms: (-)-Actinonin)

Actinonin Chemical Structure

CAS No. : 13434-13-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1100 In-stock
5 mg ￥1000 In-stock
10 mg ￥1800 In-stock
25 mg ￥3800 In-stock
50 mg ￥6800 In-stock
100 mg ￥11500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Actinonin 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Differentiation Inducing Compound Library
  • Antibacterial Compound Library
  • Antibiotics Library
  • Anti-Pancreatic Cancer Compound Library
  • Microbial Metabolite Library
  • Angiogenesis Related Compound Library

生物活性

Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities[1][2][3][4][5].

IC50 & Target

Ki: 0.28 nM (Peptide deformylase (PDF))[2], 300 nM (MMP-1), 1,700 nM (MMP-3), 190 nM (MMP-8), 330 nM (MMP-9)[3], and 20 nM (hmeprin α)[5]
Apoptosis[1]
Aminopeptidase M, Aminopeptidase N and Leucine aminopeptidase[1]
体外研究
(In Vitro)

Actinonin inhibits cell growth in various human tumor cell lines. The IC50 of 4, 6.9, 12.8, 16.6, 27.4, 15.7 and 49.3 μM for Raji cells, MDA-MB-468 cells,PC3 cells, SK-LC-19 cells, Hela cells, HT-1080 cells and AL67 cells, respectively[1].
HsPDF is a critical target of actinonin and that the inhibition of this protein in the mitochondria leads to cell death in tumor cells. Actinonin treatment of cells led to a tumor-specific mitochondrial membrane depolarization and ATP depletion in a time- and dose-dependent manner[1].
Actinonin is a potent inhibitor of all three forms (Zn-, Ni-, and Fe-) of peptide deformylases from both S. aureus and E. coli bacteria. Under the assay conditions, the IC50 values for Actinonin are 90, 3, 0.8, and 11 nM for Zn-PDF (E. coli), Ni-PDF (E. coli), Fe-PDF (E. coli), and Ni-PDF (S. aureus), respectively[2].
Actinonin is active against Gram-positive bacteria, including S. aureus (MIC value of 8-16 µg/mL), Streptococcus pyogenes (MIC value of 8 µg/mL) and Streptococcus epidermidis (MIC value of 2-4 µg/mL). Actinonin is also active against fastidious Gramne-gative bacteria, such as H. influenzae (MIC value of 1-2 µg/mL), Moraxella catarrhalis (MIC value of 0.5 µg/mL), and Neisseria gonorrheae (MIC value of 1-4 µg/mL). Actinonin is very active against the H. influenzae acr (MIC value of 0.13 µg/mL) and E. coli acr (MIC value of 0.25 µg/mL) efflux pump mutants[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Actinonin has been safely administered to mice as an antibiotic at doses up to 400 mg/kg. Actinonin does not appear to have significant toxicity to normal tissues, despite its antitumor activity in vitro. Remarkably, Actinonin exhibits significant antitumor activity when given i.p. or orally in a CWR22 human prostate tumor xenograft model in nude mice. During treatment, the animals show no signs of toxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

385.50

Formula

C19H35N3O5
CAS 号

13434-13-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (129.70 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.5940 mL 12.9702 mL 25.9403 mL
5 mM 0.5188 mL 2.5940 mL 5.1881 mL
10 mM 0.2594 mL 1.2970 mL 2.5940 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 5 mg/mL (12.97 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (12.97 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 5 mg/mL (12.97 mM); Suspended solution; Need ultrasonic

    此方案可获得 5 mg/mL (12.97 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 5 mg/mL (12.97 mM); Clear solution

    此方案可获得 ≥ 5 mg/mL (12.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Lee MD, et al. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest. 2004 Oct;114(8):1107-16.

    [2]. Chen DZ, et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry. 2000 Feb 15;39(6):1256-62.

    [3]. Wahl, R.C., et al. Hydroxamate inhibitors of human gelatinase B (92 kDa). Bioorganic & Medicinal Chemistry Letters 5(4), 349-352 (1995).

    [4]. Duke SO, et al. Modes of action of microbially-produced phytotoxins. Toxins (Basel). 2011 Aug;3(8):1038-64.

    [5]. Kruse MN, et al. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J. 2004 Mar 1;378(Pt 2):383-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CTTHWGFTLC, CYCLIC

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CTTHWGFTLC, CYCLIC 

CTTHWGFTLC, CYCLIC 是一种基质金属蛋白酶 MMP-2 和 MMP-9 的环肽抑制剂。对 MMP-9 的 IC50 约为 8 μM。

CTTHWGFTLC, CYCLIC

CTTHWGFTLC, CYCLIC Chemical Structure

CAS No. : 244082-19-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM[1].

IC50 & Target

MMP-9

 

MMP-2

 

体外研究
(In Vitro)

CTTHWGFTLC, CYCLIC inhibits endothelial and tumor cell migration in vitro[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

CTTHWGFTLC, CYCLIC inhibits tumor progression in vivo, in mouse models[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1166.33

Formula

C52H71N13O14S2
CAS 号

244082-19-7
Sequence

Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys (Disulfide Bridge: Cys1-Cys10)
Sequence Shortening

CTTHWGFTLC (Disulfide Bridge: Cys1-Cys10)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Medina OP, et al. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 2001 May 15;61(10):3978-85.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

GPLGIAGQ

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

GPLGIAGQ 

GPLGIAGQ 是一种 MMP2 可降解 (cleavable) 的多肽，在脂质体和胶束纳米载体中都被用作刺激敏感的连接物，用于 MMP2 触发的肿瘤靶向研究。GPLGIAGQ 可用于合成光动力疗法 (PDT) 中独特的MMP2靶向光敏剂。

GPLGIAGQ

GPLGIAGQ Chemical Structure

CAS No. : 109053-09-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

GPLGIAGQ 的其他形式现货产品:

GPLGIAGQ TFA

生物活性

GPLGIAGQ, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT)[1][2][3].

IC50 & Target

MMP2[1].
体外研究
(In Vitro)

GPLGIAGQ is used to trigger PEG deshielding of liposomal carriers, resulting in enhanced cellular internalization[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

711.81

Formula

C31H53N9O10
CAS 号

109053-09-0
Sequence

Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln
Sequence Shortening

GPLGIAGQ
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Hou W, et al. MMP2-Targeting and Redox-Responsive PEGylated Chlorin e6 Nanoparticles for Cancer Near-Infrared Imaging and Photodynamic Therapy. ACS Appl Mater Interfaces. 2016 Jan 20;8(2):1447-57.

    [2]. Zhu L, et al. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials. 2014 Apr;35(13):4213-22.

    [3]. Liu FH, et al. Enzyme-sensitive cytotoxic peptide-dendrimer conjugates enhance cell apoptosis and deep tumor penetration. Biomater Sci. 2018 Feb 27;6(3):604-613.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Prinomastat(Synonyms: 普啉司他; AG3340; KB-R9896)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Prinomastat (Synonyms: 普啉司他; AG3340; KB-R9896)

Prinomastat (AG3340) 是一种广谱，有效的口服活性金属蛋白酶 (MMP) 抑制剂，对于 MMP-1, MMP-3 和 MMP-9 的 IC50 分别为 79 nM，6.3 nM 和 5.0 nM。Prinomastat 抑制 MMP-2, MMP-3 和 MMP-9 的 Ki 分别为 0.05 nM，0.3 nM 和 0.26 nM。Prinomastat 穿过血脑屏障。抗肿瘤活性。

Prinomastat(Synonyms: 普啉司他; AG3340; KB-R9896)

Prinomastat Chemical Structure

CAS No. : 192329-42-3

规格 价格 是否有货
1 mg ￥1250 询问价格 & 货期
5 mg ￥3750 询问价格 & 货期
10 mg ￥6550 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3 and MMP-9 with Kis of 0.05 nM, 0.3 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity[1][2][3][4].

IC50 & Target[1][4]

MMP-9

5 nM (IC50)

MMP-9

0.26 nM (Ki)

MMP-2

0.05 nM (Ki)

MMP-1

79 nM (IC50)

MMP-3

6..3 nM (IC50)

MMP-3

0.3 nM (Ki)

体外研究
(In Vitro)

Prinomastat (AG3340; 0.1-1 µg/mL; 4 days; C57MG/Wnt1 cells) inhibits Wnt1-induced MMP-3 production. Reversal of Wnt1-induced EMT and β-catenin transcriptional activity by Prinomastat[1].
Co-culture of L/Wnt3a cells and CT7 cells increases the Topflash activity in CT7 cells, and co-culturing both L/Wnt3a cells and MMP-3 overexpressing C57MG cells with CT7 cells increases the Topflash luciferase activity in CT7 cells beyond the level observed with L/Wnt3a cells, and these effects are all suppressed by Prinomastat (AG3340)[1].
Inhibition of entry of C57MG/Wnt1 cells into S phase by Prinomastat corresponds to a decrease in expression of cyclin D1 and Erk1/2 phosphorylation. The effect of Prinomastat on Wnt1-induced migration is then examined using an in vitro wound assay. As anticipated, the migration of C57MG/Wnt1 cells is increased by 1.8-fold when compared with C57MG cells.The effect of Wnt1 on the cellular distribution of vimentin is reversed by Prinomastat in C57MG/Wnt1 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: C57MG/Wnt1 cells
Concentration: 0.1 µg/mL, 1 µg/mL
Incubation Time: 4 days
Result: A significant decrease in MMP-3 promoter activity in C57MG/Wnt1 cells.

体内研究
(In Vivo)

In a human fibrosarcoma mouse model (HT1080), the mice are treated therapeutically for 14-16 days with 50 mg/kg/day ip daily starting day 3 to 6 after tumour inoculation. Prinomastat is well tolerated by the animals, and there are no signs of weight loss or other adverse effects. Prinomastat has good tumour growth inhibition, with a short T1/2 of 1.6 hours[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

423.51

Formula

C18H21N3O5S2
CAS 号

192329-42-3
中文名称

普啉司他
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. Sørensen MD, et al. Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity. Bioorg Med Chem. 2003 Dec 1;11(24):5461-84.

    [2]. Blavier L, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT). Cancer Biol Ther. 2010 Jul 15;10(2):198-208.

    [3]. Shalinsky DR, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999 Jun 30;878:236-70.

    [4]. Ozerdem U, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res. 2000 Jun;20(6):447-53.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

GPLGIAGQ TFA

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

GPLGIAGQ TFA  纯度: 99.67%

GPLGIAGQ TFA 是一种 MMP2 可降解 (cleavable) 的多肽，在脂质体和胶束纳米载体中都被用作刺激敏感的连接物，用于 MMP2 触发的肿瘤靶向研究。GPLGIAGQ可用于合成光动力疗法 (PDT) 中独特的MMP2靶向光敏剂。

GPLGIAGQ TFA

GPLGIAGQ TFA Chemical Structure

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1360 In-stock
5 mg ￥1000 In-stock
10 mg ￥1500 In-stock
50 mg ￥3500 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

GPLGIAGQ TFA 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library
  • Peptide Library

生物活性

GPLGIAGQ TFA, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ TFA can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT)[1][2][3].

IC50 & Target

MMP2[1].
体外研究
(In Vitro)

GPLGIAGQ is used to trigger PEG deshielding of liposomal carriers, resulting in enhanced cellular internalization[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

825.83

Formula

C33H54F3N9O12
Sequence

Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln
Sequence Shortening

GPLGIAGQ
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (60.55 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2109 mL 6.0545 mL 12.1090 mL
5 mM 0.2422 mL 1.2109 mL 2.4218 mL
10 mM 0.1211 mL 0.6055 mL 1.2109 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.03 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.03 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.03 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.03 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Hou W, et al. MMP2-Targeting and Redox-Responsive PEGylated Chlorin e6 Nanoparticles for Cancer Near-Infrared Imaging and Photodynamic Therapy. ACS Appl Mater Interfaces. 2016 Jan 20;8(2):1447-57.

    [2]. Zhu L, et al. Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials. 2014 Apr;35(13):4213-22.

    [3]. Liu FH, et al. Enzyme-sensitive cytotoxic peptide-dendrimer conjugates enhance cell apoptosis and deep tumor penetration. Biomater Sci. 2018 Feb 27;6(3):604-613.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

FFAGLDD

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FFAGLDD 

FFAGLDD 是 MMP9 选择性切割肽，用于阿霉素 (DOX) 的胞质递送，并实现了时间和空间控制的缓慢药物递送和释放。

FFAGLDD

FFAGLDD Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release[1].

IC50 & Target[1]

MMP9

 

分子量

783.82

Formula

C37H49N7O12
Sequence Shortening

FFAGLDD
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhou Q, et al. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int J Nanomedicine. 2018 May 18;13:2921-2942.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

FFAGLDD

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FFAGLDD 

FFAGLDD 是 MMP9 选择性切割肽，用于阿霉素 (DOX) 的胞质递送，并实现了时间和空间控制的缓慢药物递送和释放。

FFAGLDD

FFAGLDD Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release[1].

IC50 & Target[1]

MMP9

 

分子量

783.82

Formula

C37H49N7O12
Sequence Shortening

FFAGLDD
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhou Q, et al. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int J Nanomedicine. 2018 May 18;13:2921-2942.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

FFAGLDD

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

FFAGLDD 

FFAGLDD 是 MMP9 选择性切割肽，用于阿霉素 (DOX) 的胞质递送，并实现了时间和空间控制的缓慢药物递送和释放。

FFAGLDD

FFAGLDD Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release[1].

IC50 & Target[1]

MMP9

 

分子量

783.82

Formula

C37H49N7O12
Sequence Shortening

FFAGLDD
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Zhou Q, et al. Stimuli-responsive polymeric micelles for drug delivery and cancer therapy. Int J Nanomedicine. 2018 May 18;13:2921-2942.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

多肽定制MMP Biotinylated Substrate I 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Biotinylated Substrate I
编码
别名 MMP Biotinylated Substrate I
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） Biotin-LCPLGLRAY-NH2
序列（三字母缩写） Biotin-LC-Pro-Leu-Gly-Leu-Arg-Ala-Tyr-NH2
基本描述
溶解度
分子量 1127.43
化学式 C53H86N14O11
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Biotinylated Substrate I 编码
Figures MMP Biotinylated Substrate I 编码
Reference
C端
N端
化学桥

多肽定制MMP Inhibitor 1 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Inhibitor 1
编码
别名 MMP Inhibitor 1
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） Abz-GP-DLeu-DAla-NH-OH
序列（三字母缩写） H-Abz-Gly-Pro-DLeu-DAla-NH-OH (trifluoroacetate salt)
基本描述
溶解度
分子量 491.6
化学式 C23H35N6O6
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Inhibitor 1 编码
Figures MMP Inhibitor 1 编码
Reference S. Odake, et al., Biochem. Biophys. Res. Commun. 199, 1442 (1994)
C端
N端
化学桥

多肽定制MMP Substrate I, fluorogenic 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Substrate I, fluorogenic
编码
别名 MMP Substrate I, fluorogenic
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） DNPPLGLWAr-NH2
序列（三字母缩写） Dnp-Pro-Leu-Gly-Leu-Trp-Ala-D-Arg-NH2
基本描述
溶解度
分子量 977.1
化学式 C45H64N14O11
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Substrate I, fluorogenic 编码
Figures MMP Substrate I, fluorogenic 编码
Reference
C端
N端
化学桥

多肽定制MMP Substrate II, Control 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Substrate II, Control
编码
别名 MMP Substrate II, Control
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） Dnp-GPLG
序列（三字母缩写） DNP-Gly-Pro-Leu-Gly-OH
基本描述 Efficient substrate for intestitial/vertebrate collagenase (MMP-1), stromelysin (MMP-3), gelatinases (MMP-2 and MMP-9) and the punctuated metalloproteinase (MMP-7).
溶解度
分子量 0
化学式 C21H28N6O9
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Substrate II, Control 编码
Figures MMP Substrate II, Control 编码
Reference S.J. Deng, et al., J. Biol. Chem. 275, 31422 ( 2000)
C端
N端
化学桥

多肽定制MMP Substrate III, Fluorogenic 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Substrate III, Fluorogenic
编码
别名 MMP Substrate III, Fluorogenic
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） Dabcyl-GABA-PQGL-Glu(EDANS)-AK-NH2
序列（三字母缩写） DABCYL-GABA-Pro-Gln-Gly-Leu-Glu(EDANS)-Ala-Lys-NH2?(trifluoroacetate salt)
基本描述 Selective fluorogenic matrix metalloproteinase (MMP) substrate with the following Kcat/Km value for MMP-3 (Stromelysiin-1) is 29.0 M-1s-1, for MMP-13 13.0 M-1s-1, and for MMP-9 7.5 M-1s-1?(at pH = 7.5, 25°C). The fluorescence increase is measured using an wavelength of 360 nm and an emission wavelength of 490 nm. No activity against this substrate could be measured with MMP-1, MMP-7, and MMP-8.
溶解度
分子量 1325.6
化学式 C63H88N16O14S1
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Substrate III, Fluorogenic 编码
Figures MMP Substrate III, Fluorogenic 编码
Reference B. Beekman, et al., FEBS Lett, 390, 221 ( 1996)
C端
N端
化学桥

多肽定制MMP Substrate IV, Fluorogenic 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Substrate IV, Fluorogenic
编码
别名 MMP Substrate IV, Fluorogenic
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） Dabcyl-GABA-RPKPVE-Nva-WR-Glu(EDANS)-AK-NH2
序列（三字母缩写） DABCYL-GABA-Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg-Glu(EDANS)-Ala-Lys-NH2?(trifluoroacetate salt)
基本描述
溶解度
分子量 2078.5
化学式 C99H144N28O20S1
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Substrate IV, Fluorogenic 编码
Figures MMP Substrate IV, Fluorogenic 编码
Reference Beekman, B., et al., 1997. FEBS Lett 418, 305.
C端
N端
化学桥

多肽定制MMP Substrate V, Fluorogenic 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Substrate V, Fluorogenic
编码
别名 MMP Substrate V, Fluorogenic
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） FITC-C6-PLALWAR-Lys(Biotin)-NH2
序列（三字母缩写） FITC-C6-Pro-Leu-Ala-Leu-Trp-Ala-Arg-Lys(Biotin)-NH2?(trifluoroacetate salt)
基本描述 Substrate that is hydrolyzed 60 times more rapidly by stromelysin 1 (MMP-3) (kcat/Km= 59400 M-1s-1) than by interstitial collagenase (MMP-1). However, it presents little discrimination between MMP-3, gelatinase A (MMP-2)(kcat/Km= 5400 M-1s-1), and gelatinase B (MMP-9)(kcat/Km= 55300 M-1s-1).
溶解度
分子量 1682.02
化学式 C83H112N18O16S2
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Substrate V, Fluorogenic 编码
Figures MMP Substrate V, Fluorogenic 编码
Reference E.J. Jacobsen, et al., J. Med. Chem. 42, 1525 (1999) J.V. Manetta, et al., Anal. Biochem. 202, 10 (1992)
C端
N端
化学桥

多肽定制MMP Substrate, Fluorogenic 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP Substrate, Fluorogenic
编码
别名 MMP Substrate, Fluorogenic
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） Dnp-PLGLWA-DArg-NH2
序列（三字母缩写） DNP-Pro-Leu-Gly-Leu-Trp-Ala-DArg-NH2?(trifluoroacetate salt)
基本描述 Highly soluble fluorogenic matrix metalloproteinase (MMP) substrate with the following kcat/km values (at pH 7.6, 37°C): 619.0 M-1s-1?for MMP-2, 209.0 M-1s-1?for MMP-9, 40.0 M-1s-1?for MMP-3, 21.0 M-1s-1?for MMP-1. The fluorescence increase is measured using an wavelength of 340 nm and emission wavelength of 485 nm. The relative high emission wavelength of EDANS allows convenient measurement of MMP activity in complex biological media like synovial fluid and culture medium.
溶解度
分子量 977.1
化学式 C45H64N14O11
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP Substrate, Fluorogenic 编码
Figures MMP Substrate, Fluorogenic 编码
Reference D.M. Bickett, et al., Anal. Biochem. 212, 58 (1993) C.G. Knight, et al., FEBS Lett. 296, 263 (1992) K. Darlak, et al., J. Biol. Chem. 265, 5199 (1990) M.S. Stack, and R.D. Gray, J. Biol. Chem. 264, 4277 (1989)
C端
N端
化学桥

多肽定制MMP-1 Substrate I, Fluorogenic 编码

发表于由

上海金畔生物科技有限公司可以定制不同序列多肽，可以访问官网了解更多产品信息。

名称 MMP-1 Substrate I, Fluorogenic
编码
别名 MMP-1 Substrate I, Fluorogenic
纯度 80%，90%，95%，98%，99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列（单字母缩写） DNP-PLALWAR
序列（三字母缩写） DNP-Pro-Leu-Ala-Leu-Trp-Ala-Arg-OH (trifluoroacetate salt)
基本描述 Efficient substrate for interstitial/vertebrate collagenase (MMP-1), stromelysin (MMP-3), gelatinases (MMP-2 and MMP-9) and punctuated metalloproteinase (MMP-7).
溶解度
分子量 0
化学式 C46H65N13O12
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents MMP-1 Substrate I, Fluorogenic 编码
Figures MMP-1 Substrate I, Fluorogenic 编码
Reference S. Netzel-Arnett, et al., Anal. Biochem. 195, 86 (1991)
C端
N端
化学桥